METASTATIC UROTHELIAL CARCINOMA
Clinical trials for METASTATIC UROTHELIAL CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new METASTATIC UROTHELIAL CARCINOMA trials appear
Sign up with your email to follow new studies for METASTATIC UROTHELIAL CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Two-Drug attack tested for Tough-to-Treat bladder cancer
Disease control TerminatedThis early-phase study tested a combination of two drugs, selinexor and pembrolizumab, for patients with advanced bladder cancer who could not receive or did not respond to standard chemotherapy. The goal was to find a safe dose and see if the combination could shrink tumors. The…
Matched conditions: METASTATIC UROTHELIAL CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Mamta Parikh • Aim: Disease control
Last updated Mar 30, 2026 14:34 UTC
-
Targeted attack: new combo therapy tested for tough bladder cancers
Disease control TerminatedThis study aimed to see if a new drug combination (pemigatinib plus pembrolizumab) worked better than standard care for people with advanced bladder cancer who cannot take cisplatin and have a specific genetic change (FGFR3). It was a Phase 2 trial that was terminated early, enro…
Matched conditions: METASTATIC UROTHELIAL CARCINOMA
Phase: PHASE2 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Mar 30, 2026 14:31 UTC